The prototypes of the devices awarded with a grant from research venture Zcube: they are the result of the intuition and scientific research of dr. Lazzaro Di Biase, young neurologist fromUniversità Campus Bio-Medico di Roma, which created a start-up to validate and create them and hopes to make them available by 2020

 

Rome, April 19, 2018   Four tools capable of keeping Parkinson's disease at bay and, consequently, bringing the expectation - but above all the quality - of life of these patients to the level of their healthy peers: they are the most interesting and promising novelty presented during the launch of the 'Open Accelerator' event, held today at the headquarters of the pharmaceutical company Zambon, in Bresso (MI).

The appliances were devised by dr. Lazzaro Di Biase, 32 years old, neurologist and doctoral student of theUniversità Campus Bio-Medico di Roma, who just created one start-up - PD Innovations (PD stands for Parkinson's Disease, or 'Parkinson's disease') - just formake effective early diagnosis possible, Monitoring of the evolution of the pathology and the treatment management, both oral and infusion, in real time and based on technical clinical conditions of each individual patient.

"Currently – explains Di Biase – the diagnostic error in Parkinson's is 30 percent at any stage of the disease. A few months ago we created a particular 'watch', equipped with a algorithm capable of reducing this percentage to 8 percent. With the new device we trust to be able to bring this margin of error to almost zero”. That's also why the discovery of him was awarded last December 12th, just from Zcube, which will finance the research and development of the devices with 25 thousand euros.

In fact, the problem of Parkinson's today is precisely early diagnosis: this pathology cannot be cured, but it is possible to live with it if it is diagnosed early and treated pharmacologically. The Available therapies, in fact, are effective in improving motor symptoms, especially in the early stages of the disease. But next to the Parkinsonian patient 'doc' it is possible to find many people suffering from 'essential tremor' or come onso-called 'atypical parkinsonisms'Very difficult to distinguish in the early stages even when observed by experienced specialists. Usually, when it is possible to 'frame' the pathology with certainty, several years have passed by now.

"On these cases we want to affect with our devices – underlines Di Biase – even because generally you can die of Parkinson's, but the risk of death is often linked to its complications: the inability to move which can produce falls and therefore broken femur, or bed rest, ulcers and pneumonia. If, conversely, it becomes possible to maintain mobility throughout the life of a Parkinsonian, his expectation of life could reach that of a healthy person".

Il Parkinson's disease is, among the neurological pathologies, the one with the currently most effective therapies, though there are no real cures to block or slow the development of the disease. “Our algorithm – explains di Biase again – will be able to analyze the global movement of the patient, all in a minimally invasive way: the sensors present in a normal smartphone will suffice”. A novelty that, therefore, could be used by all doctors, even the basic ones, and who will put them able to issue an unequivocal diagnostic response compared to a Parkinson's hypothesis, already in the very early stages of the disease.

"Not only continues di Biase –, we are also working on one tool to optimize the effectiveness of therapies, which through implantable micro-sensors will be able to 'dosing' the most suitable and indicated amount of drug for the specific conditions of the patient, varying it if necessary by the hour, in order to always keep it adequately mobile”. “A system similar to what exists today for people with diabetes (the needle under the skin that 'reads' the blood sugar and releases the amount of insulin necessary to keep it within a range established, ed)”, clarifies Di Biase.

The researcher ofUniversità Campus Bio-Medico di Roma he is confident that he will be able to complete all the trials clinicians of validation of the four device by 2020. At that point, if all goes as hoped, another life could really begin for Parkinson's patients: a day no longer plagued by multiple daily fluctuations in one's ability to move – between moments of motor 'block', phases characterized by involuntary movements and others in which it is once again possible to control one's body. In short, the future dream of a better life for these patients could already be almost present.